Results 31 to 40 of about 1,763 (188)

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives [PDF]

open access: yesCurrent Oncology
The management of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after progression on osimertinib is becoming increasingly complex, particularly in Canada, where access to diagnostic testing and newer therapies ...
Nathalie Daaboul   +16 more
doaj   +2 more sources

Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study. [PDF]

open access: yesBreast
Background: Patients with visceral oligoprogressive and oligopersistent metastatic breast cancer (mBC) may benefit from metastasis-directed thermal ablation (TA) to all sites of metastasis, while maintaining the same systemic treatment, in order to delay
Bianco N   +17 more
europepmc   +2 more sources

First-line osimertinib in advanced [PDF]

open access: yesESMO Real World Data and Digital Oncology
Background: First-line osimertinib is standard for advanced EGFR -mutated non-small-cell lung cancer (NSCLC), but upfront combinations (FLAURA2, MARIPOSA) are reshaping this paradigm.
G. Suay   +17 more
doaj   +2 more sources

The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study [PDF]

open access: yesThoracic Cancer
Background In metastatic non‐small cell lung cancer (NSCLC) patients receiving first‐line immune checkpoint inhibitors (ICIs), the real‐world progression patterns and subsequent treatment outcomes remain controversial. Methods We retrospectively analyzed
Qi He   +8 more
doaj   +2 more sources

The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer [PDF]

open access: yes, 2021
Objectives: Patients with advanced stage non-small cell lung cancer (NSCLC) are generally considered incurable. The mainstay of treatment for these patients is systemic therapy.
Hartemink, K.J.   +17 more
core   +1 more source

Oligoprogression in Non-Small Cell Lung Cancer

open access: yesCancers, 2021
We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease ...
Daijiro Harada, Nagio Takigawa
openaire   +3 more sources

The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer [PDF]

open access: yesDeutsches Ärzteblatt international, 2019
Systemic treatment is standard for most types of cancer with disseminated metastases. The role of local treatment (LT) of individual tumor foci in patients with oligometastatic disease is unclear and the object of current scientific studies.This review is based on pertinent publications retrieved by a selective search in PubMed.Four randomized trials ...
Jan, Haussmann   +5 more
openaire   +2 more sources

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-Based Review

open access: yesCurrent Oncology, 2023
For decades, the distant progression of breast cancer has been the purview of systemic therapy alone or with low to moderate-dose radiation therapy intended for the palliation of symptomatic metastases.
Gary M. Freedman   +2 more
doaj   +1 more source

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

open access: yesTherapeutic Advances in Medical Oncology, 2023
Background: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (
Wendi Xuzhang   +5 more
doaj   +1 more source

Stereotactic body radiotherapy for oligoprogressive cancer [PDF]

open access: yesThe British Journal of Radiology, 2016
Stereotactic body radiotherapy (SBRT) is a focused tumour treatment that produces high local control rates with low toxicity. Its use in metastatic cancer is evolving rapidly, with purported benefits in the oligometastatic setting and for better palliation of symptomatic disease.
openaire   +2 more sources

Home - About - Disclaimer - Privacy